Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Journey Medical (DERM) EBITDA Margin (2020 - 2026)

Journey Medical filings provide 6 years of EBITDA Margin readings, the most recent being 34.55% for Q4 2025.

  • On a quarterly basis, EBITDA Margin rose 1685.0% to 34.55% in Q4 2025 year-over-year; TTM through Dec 2025 was 3.94%, a 2087.0% increase, with the full-year FY2025 number at 3.9%, up 2091.0% from a year prior.
  • EBITDA Margin hit 34.55% in Q4 2025 for Journey Medical, up from 8.98% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 112.87% in Q3 2023 to a low of 90.02% in Q2 2021.
  • Median EBITDA Margin over the past 5 years was 22.54% (2024), compared with a mean of 26.03%.
  • Biggest five-year swings in EBITDA Margin: skyrocketed 17177bps in 2023 and later plummeted -13265bps in 2024.
  • Journey Medical's EBITDA Margin stood at 51.7% in 2021, then crashed by -45bps to 75.2% in 2022, then skyrocketed by 82bps to 13.79% in 2023, then soared by 228bps to 17.7% in 2024, then skyrocketed by 95bps to 34.55% in 2025.
  • The last three reported values for EBITDA Margin were 34.55% (Q4 2025), 8.98% (Q3 2025), and 19.16% (Q2 2025) per Business Quant data.